Tata India Pharma and Healthcare Fund Regular Plan Growth
Tata Mutual Fund
₹31.31 (+0.34%)
NAV as of 9 Oct 2026
Minimum Investment: ₹5,000
Return
2.53% Returns for 1Y
Expense ratio & Others
- Net expense ratio
- 2.13%
- Exit load
- 0%
- Lock-in
- No
- Minimum investment
- ₹5,000
- Category
- Sector - Healthcare
Expense ratio is inclusive of GST. Returns may be taxed based on the fund type and your holding period — please read the scheme-related documents and consult a tax advisor. Figures are historical and do not guarantee future results.
Fund Returns Estimator
One-time investment
₹1,000
6 months
₹1,091
Invested ₹1,000
▲+9.07%1 year
₹1,025
Invested ₹1,000
▲+2.53%3 years
₹1,162
Invested ₹1,000
▲+16.19%5 years
₹1,119
Invested ₹1,000
▲+11.91%
Based on the fund’s historic trailing returns — a planning illustration, not a guarantee of future results.
Invest One-TimePlan it your way
The figures above are fixed to this fund’s past returns over set periods. Use a calculator to set your own amount, tenure and expected rate of return.
Risk level
Riskometer scale
- Low
- Low to Moderate
- Moderate
- Moderate to High
- High
- Very HighThis fund
Riskometer level assigned by the fund house as per SEBI norms. It can change as the scheme’s portfolio changes.
Fund benchmark
| Primary Index Name | BSE Healthcare PR INR |
|---|---|
| Secondary Index Name | BSE Healthcare PR |
| Index Name | Nifty Pharma TR INR |
| Weighting | 100% |
Returns
| 1Y | 3Y | 5Y | 10Y | |
|---|---|---|---|---|
| Fund returns (%) | +2.53% | +16.19% | +11.91% | — |
| Cumulative returns (%) | +2.53% | +56.84% | +75.55% | +228.11% |
Fund Manager
| Manager | Rajat Srivastava |
|---|---|
| Role | Manager |
| Manager Tenure | 2.04 yrs |
About Fund
| Date of Incorporation | 28 Dec 2015 |
|---|---|
| Fund House | Tata Mutual Fund |
| Custodian | Deutsche Bank AG |
| Registrar / Transfer Agent | Tata Asset Management Pvt Ltd |
| Address | 1 Great Winchester Street |
Top Holdings
| Company | Weightage (%) |
|---|---|
| Sun Pharmaceuticals Industries Ltd | 7.99% |
| Abbott India Ltd | 5.94% |
| HealthCare Global Enterprises Ltd | 5.92% |
| Divi's Laboratories Ltd | 5.68% |
| GlaxoSmithKline Pharmaceuticals Ltd | 4.66% |
| Dr Reddy's Laboratories Ltd | 4.65% |
| Aster DM Healthcare Ltd Ordinary Shares | 4.63% |
| Alkem Laboratories Ltd | 4.42% |
| Apollo Hospitals Enterprise Ltd | 4.36% |
| Rainbow Childrens Medicare Ltd | 4.30% |
| Cipla Ltd | 4.22% |
| Mankind Pharma Ltd | 3.77% |
| Torrent Pharmaceuticals Ltd | 3.76% |
| Ipca Laboratories Ltd | 3.72% |
| Max Healthcare Institute Ltd Ordinary Shares | 3.71% |
| Lupin Ltd | 3.57% |
| J.B. Chemicals & Pharmaceuticals Ltd | 3.52% |
| Bayer CropScience Ltd | 3.51% |
| Ajanta Pharma Ltd | 3.45% |
| Fortis Healthcare Ltd | 3.30% |
Investment Strategy
The investment objective of the scheme is to seek long term capital appreciation by investing atleast 80% of its net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.
Mutual fund investments are subject to market risks. Read all scheme-related documents carefully. The data shown is for information only and does not constitute investment advice.